Compounders hold on in the GLP-1 market

Despite a year of FDA enforcement actions and lawsuits from Novo Nordisk and Eli Lilly, compounding pharmacies still hold a notable share of the GLP-1 weight-loss market. A Gallup survey of 5,065 U.S. adults conducted May 28 to June 5, 2026, found that 15% of Americans have tried a GLP-1 weight-loss drug at some point. Of current users, 19% reported taking a compounded or custom-mixed version, and a further 12% were unsure whether they used a brand-name product^[1].

How compounders captured the market

The opportunity opened in 2022. Demand for semaglutide and tirzepatide outpaced Novo Nordisk and Eli Lilly's manufacturing capacity, and the FDA placed both active ingredients on its drug shortage list. Under U.S. law, that designation lets compounding pharmacies produce copies without the normal approval pathway. Large 503B outsourcing facilities began filling millions of prescriptions. At peak in 2024, compounded versions accounted for an estimated 30% of the overall GLP-1 market^[2].

The economics were straightforward. Brand-name Wegovy and Zepbound carry list prices above $1,000 per month before insurance. Compounded semaglutide typically runs a fraction of that. The Gallup data make the cost calculus explicit: 66% of compounded-drug users who had previously taken brand-name versions cited cost or insurance coverage as the primary reason for switching.

What changed when the shortage ended

The FDA removed semaglutide and tirzepatide from the shortage list in late 2024 and early 2025. That step should, in principle, have ended the legal basis for large-scale compounding of those molecules. In practice, the transition stalled. Telehealth platforms including Hims and Hers pivoted to offering "personalised" formulations, which remain permissible under a different legal category. An estimated two million Americans per month were still receiving compounded versions from large outsourcing facilities as of the first half of 2025^[2].

The FDA has responded in layers. In May 2026 it proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, the mechanism that allows 503B facilities to produce large batches without individual patient prescriptions. If that proposal is finalised, it would close the largest remaining pathway for industrial-scale compounding of GLP-1 drugs^[2]. The agency also issued a drug alert in June 2026 warning patients and providers about unapproved GLP-1 products, citing 1,700 adverse event reports linked to compounded semaglutide and tirzepatide as of late May 2026.

Lawsuits and settlements

Novo Nordisk filed patent infringement cases against at least 21 producers of compounded semaglutide. The highest-profile resolution involved Hims and Hers: the two sides reached a settlement in which the telehealth platform agreed to stop advertising compounded alternatives and instead offer Wegovy, with Novo retaining rights to revive the case if the arrangement breaks down. Eli Lilly pursued a parallel track against compounders of tirzepatide. Neither company has seen the compounding channel close entirely as a result^[2].

Safety and screening gaps

The clinical concern is not limited to product quality. A JAMA research letter found that 55% of 49 online GLP-1 sellers failed to ask patients about their history of eating disorders before dispensing, a screening step recommended in clinical guidance for the class^[2]. The FDA's adverse event log of 1,700 reports covers dosing errors, contamination, and other harms attributed to compounded formulations, though the absolute figure must be read against the volume of prescriptions involved.

Why the share is unlikely to collapse quickly

Four structural factors keep compounders in the market. First, cost: brand-name GLP-1 drugs remain unaffordable for many patients without generous insurance. Second, access: supply constraints for branded products have eased but not vanished everywhere. Third, legal complexity: the "personalised" formulation workaround and ongoing court challenges mean no single ruling removes all compounders at once. Fourth, habit: 35% of compounded-drug users previously took brand-name versions and switched deliberately. For context on what grey-market risks look like in practice, see the guides on semaglutide grey-market risks and tirzepatide grey-market risks.

What to watch next

The FDA's 503B Bulks List proposal is the most consequential pending action. If finalised, it would restrict large-scale outsourcing facilities while leaving smaller 503A compounding pharmacies able to produce on a patient-specific basis, a much narrower channel. Court challenges from compounders and telehealth platforms are expected. The Gallup data will be worth revisiting once the regulatory picture settles, because the 19% compounded-user share represents a ceiling set by today's legal ambiguity, not a floor. For the regulatory status of semaglutide and tirzepatide in specific markets, see the semaglutide regulation pages and the tirzepatide regulation pages.

This article is for informational purposes only and does not constitute medical or legal advice. Readers should consult a qualified healthcare provider before making any decisions about prescription medications.